We have previously shown that treatment of nonobese gallstone patients with 13-15 mg chenodeoxycholic acid (CDCA)/kg/day almost always produces unsaturated bile and dissolves gallstones,' while, in the obese, 18-22 mg/kg/day of CDCA are needed to produce the same effect.2 From a total of 125 patients with radiolucent gallstones in functioning gallbladders treated with CDCA, we have identifed seven who, despite being given 19-22 mg/kg/day, never developed unsaturated bile nor did their gallstones dissolve. In this paper we describe the clinical details in this 'resistant' group and, in an attempt to define the mechanism for the non-response, we measured hepatic cholesterol synthesis as judged by the activity of the rate limiting enzyme in cholesterogenesis, HMGCoA
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Methods

PATIENTS AND STUDY DESIGN
Clinical details in the seven 'resistant' patients. studied are given in Table 1 . There were four men and three women whose ages ranged from 29 to 68 years. Four were non-obese-arbitrarily defined as less than 120% of ideal body weight (range 102 to 119% IBW), and three were obese-137 to 168% IBW. All the patients started treatment with an initial dose of 13-15 mg CDCA/kg/day, but were subsequently given larger amounts of CDCA-the doses shown in Table 1 together with the corresponding data for bile lipid and biliary acid composition. None of the patients was diabetic or hyperlipidaemic-factors known to influence bile lipid composition,34 none was taking medications other than CDCA, and the women were all post-menopausal, which therefore excluded the possibility of changes in bile lipid composition known to occur during the menstrual cycle.5
The criteria for non-response to CDCA treatment were: (1) radiolucent stones in 'functioning' gallbladders, (2) supersaturated fasting duodenal 'bile' on at least two occasions despite 19 mg or more CDCA/kg/day for a minimum of six weeks, (3) 70°o r more CDCA conjugates in biliary bile acids, of the gallstone analyses and of HMGCoAR and hepatic cholesterol content are given in Table 2 .
BILE LIPID AND BILIARY BILE ACID COMPOSITION
Before treatment all patients had supersaturated bile, the mean saturation index being 1'88±SEM 0.16. During therapy, although CDCA reduced the saturation index in five of the seven patients, even with the highest CDCA doses the mean posttreatment SI was still l37 (± SEM 0.13). Biliary bile acid analyses showed that in all seven patients, the bile had become 'cheno-rich', the CDCA conjugates accounting for 70-97% of the bile acid total. The patient who took 19 mg UDCA /kg/day developed 'urso-rich' bile, his UDCA conjugates making up 67 % of his biliary bile acid total.
At this stage he developed unsaturated bile (SI= 082).
HMGCOA REDUCTASE ACTIVITY The Figure shows the present results for hepatic HMGCoA reductase activity together with our previous data for untreated cholesterol gallstone patients and for those given standard doses (13-15 mg/kg/day) of CDCA.
In the three patients who had discontinued treatment before surgery (Table 2, nos. 3, 4, and 5) the mean HMGCoAR level of 50.2 pmol/mg microsomal protein/min was considerably higher than that in our corresponding group of untreated gallstone patients (32.2+2-0; P <0-05). In the two remaining patients (nos. 1 and 2 in Table 2 ), who had taken high doses of CDCA until the eve of cholecystectomy, the mean enzyme activity of 33.5 units was more than twice that found previously12 in gallstone patients given smaller doses of CDCA (15.7J±15; p <0-01).
HEPATIC CHOLESTEROL CONTENT
The mean whole liver homogenate cholesterol content was comparable in the three patients who had stopped treatment before surgery (2-94 mg/g wet weight of liver) and in the two patients who continued CDCA until the time of operation (3.20 and 2-98 mg/g wet weight of liver). A similar pattern of results was found for microsomal cholesterol (Table 2) .
On the basis of these results, it seems that the tissue cholesterol content in patients who are resistant to CDCA is not related to HMGCoA reductase activity.
GALLSTONE ANALYSES
As the results of Table 2 show, the five patients with radiolucent stones who came to surgery all proved to have cholesterol-rich stones containing 82-100% cholesterol by weight.
Discussion
The present results suggest that there is a small number of cholesterol gallstone patients, both obese and non-obese, who do not respond predictably to CDCA. Despite taking 19-22 mg CDCA/kg/day, they failed to achieve unsaturated bile and their gallstones did not dissolve. This lack of response may be related to the fact that they had high or unsuppressed hepatic cholesterol synthesis.
DIFFERENCES BETWEEN PATIENTS IN PRESENT STUDY AND 'RESISTANCE TO CDCA TREATMENT IN OBESITY
The present group of patients were both obese and non-obese-unlike the previous group of 'resistant' patients who were all obese.2 And, although in both groups the bile remained supersaturated during treatment with the standard dose of 13-15 mg CDCA/kg/day, in the previous group the bile ultimately became unsaturated with 18-22 mg CDCA/kg/day. With the higher CDCA doses, the gallstones in four of the eight obese 'resistant' patients subsequently dissolved; in the present group, there was no evidence of gallstone dissolution with comparably high doses, even though the radiolucent stones proved to be cholesterol-rich in the five patients who came to cholecystectomy.
DEFINITION OF 'LACK OF RESPONSE'
With duodenal intubation, one can decide within the first few weeks of starting treatment whether or not criteria (2) and (3)-as described in 'Patients and study design' to define non-response to CDCAhave been fulfilled. Ultimately, however, before one can accept that the patients are truly 'resistant' to CDCA, one must ensure that they are taking the doses of CDCA prescribed. The fact that all seven had at least 70/O%CDCA conjugates in bile means thafthere was little room for further enrichment of their bile with CDCA.
There were several other differences between the patients in the present study and those described previously. From our earlier reports,216 the mean pretreatment SI in much larger numbers of patients was 1 44±0107 compared With FSS n046 in the present group. This great&r degree-of-supersaturation in the present study was not simply a function of obesity-a factor known to further increase biliary cholesterol saturation in patients with or without gallstones"7-as the pretreatment SIs were comparable in the obese and non-obese patients who failed to respond. However, the lack of response described here was probably not due to the high pretreatment SIs alone. We have previously shown that, in non-resistant gallstone patients, the greater the initial supersaturation, the greater is the fall in saturation index during treatment.2 16 In the present patients, the bile was not totally resistant to treatment, as chenotherapy reduced the SI in most cases but the degree of change was inadequate.
MECHANISM FOR LACK OF RESPONSE
Although the results of this paper suggest that the lack of response to CDCA was due to high or unsuppressed hepatic cholesterol synthesis, this hypothesis remains unproven. The high HMGCoAR activity in the two treated non-responsive patients was comparable to that found normally in untreated cholelithiasis. It may well be that the on-treatment results in these two patients had indeed been reduced by chenotherapy from an excessively high pretreatment value. Alternatively, the enzyme levels may have failed totally to respond to CDCA. 
